Rani Therapeutics Highlights Oral Biologics Pipeline at Canaccord Genuity Conference
Rani Therapeutics presented its ongoing strategic push into oral biologics at the recent Canaccord Genuity conference.
Rani Therapeutics outlined its ongoing development strategy for oral biologics during its presentation at the Canaccord Genuity conference.
The company focused on advancing its proprietary delivery technologies designed to replace traditional subcutaneous or intravenous injections of biological drugs with oral administration options. Additional details concerning clinical timelines, regulatory milestones, or financial projections from the presentation were not immediately available.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →
